Issue

Vol. 64 No. 7: Issue 7

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

ROS related enzyme levels and its association to molecular signaling pathway in the development of head and neck cancer

https://doi.org/10.14715/cmb/2018.64.7.5
Elif Sinem Iplik
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul Yeni Yuzyil University, Istanbul, Turkey
Baris Ertugrul
Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Gonca Candan
Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Saim Pamuk
Department of Otorhinolaryngology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
Levent Aydemir
Department of Otorhinolaryngology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
Mehmet Celik
Department of Otorhinolaryngology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
Murat Ulusan
Department of Otorhinolaryngology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
Arzu Ergen
Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Bedia Cakmakoglu
Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey

Corresponding Author(s) : Bedia Cakmakoglu

bedia@istanbul.edu.tr

Cellular and Molecular Biology, Vol. 64 No. 7: Issue 7

Abstract

Given the prevalence and annual incidence of cancer, head and neck cancer is affecting more than 600,000 people each year. In this research, it was decided to investigate that which genes are involved and how MPO, NQO1, SOD2 enzyme levels effective to develop of head and neck cancer and for the first time at the tissue level. 35 tumor tissues in all head and neck anatomy and their surrounding tissue (70 in total) were enclosed the research that received surgery. Determination of the apoptosis genes expression levels (Mtch1, Akt1, Caspase3, Caspase9, Bcl2, Mdm2, mTOR) were determined by RT-PCR techniques and the same patients' sample used for ROS associated oxidant-antioxidant system by using MPO, NQO1, SOD2 enzyme levels using ELISA method. According to statistical results, caspase 9 gene was found statistically high expressed in early stage in contrast to late stage (p=0,013). Level of SOD2, NQO1 and MPO was determined and only MPO level was found significantly important on tumor tissues p=0,008).  Specially, our findings for high expression of Cas9 on early stage were thought to be the target for treatment with its well-known initiator role of the apoptosis. Our results suggest that the higher level of MPO in tumor tissues and indicates that it has some role on pathology of head and neck cancers. We believe that, our research will lead the proposal in-vivo studies and will open new areas on therapeutic targets.

Keywords

Head and neck cancer Mtch1 Akt1 Caspase3 Caspase9 Bcl2 Mdm2 mTOR SOD2 NQO1 MPO.
Iplik, E. S., Ertugrul, B., Candan, G., Pamuk, S., Aydemir, L., Celik, M., Ulusan, M., Ergen, A., & Cakmakoglu, B. (2018). ROS related enzyme levels and its association to molecular signaling pathway in the development of head and neck cancer. Cellular and Molecular Biology, 64(7), 24–29. https://doi.org/10.14715/cmb/2018.64.7.5
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Parkin DM, Laara E, Muri CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97.
  2. Boring CC, Squries TS, Tong T, Montgomery S. Cancer statistics 1994. CA Cancer J Clin 1994;44,7-26.
  3. Howell RE, Wright BA, Dewar R. Trends in the incidence oforal cancer in Nova Scotia from 1983 to 1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:205-212.
  4. Tuttle TR, Mierzwa ML, Wells SI, Fox SR, Ben-Jonathan N. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. Cancer Letters 2016;370, 279–285.
  5. Roh JL, Park JY, Kim EH, Jang HJ. Targeting acid ceramidase sensitises head and neck cancer to cisplatin. European Journal of Cancer 2016;52:163e172.
  6. Denaro N, Russi EG, Adamo V, Merlano MC. State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. Oncology 2014;86:212–229.
  7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics CA Cancer J Clin 2011;61:69e90.
  8. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143e54.
  9. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced carcinogenesis. Chem Res Toxicol 2008;21:733–744.
  10. Mao L, Hong WK, Vassiliki A. Papadimitrakopoulou, Focus on head and neck cancer. Cancer cell 2004; 5:311-316.
  11. Kim L, King T, Agulnik M. Head and neck cancer: changing epidemiology and public health implications. Oncology 2010;24:915–919, 924.
  12. Brachman DG. Molecular biology head and neck cancer. Seminars in Oncol 1994;21:320-329.
  13. Shin DM, Honk WK. Genetic biomarkers and ehemoprevention. Contcmporary Oncol 1994;26 – 37.
  14. WHO Global Oral Health Programme, The World Oral Health Report 2003, Geneva, 2003.
  15. Nagler R, Savulescu D, Gavish M. Cigarette smoke-induced reduction in binding of the salivary translocator protein is not mediated by free radicals. Biochimie 2016;121:1-4.
  16. Yamamoto N, Onda T, Sugahara K, Nomura T, Shibahar T. Molecular biological change in oral cancer, summary of our researches. Japanese Dental Science Review 2015;51:25-33.
  17. Mena S, Ortega A, Estrela JM. Oxidative stress in environmental-induced carcinogenesis. Mutation Research 2009;674:36–44.
  18. Limón-Pacheco J, Gonsebatt ME. The role of antioxidants and antioxidant-related enzymes in protective responses to environmentally induced oxidative stress. Mutation Research 2009;674:137–147.
  19. Moller P, Folkmann JK, Forchhammer L, Brauner EV, Danielsen P, Rison L, et al. Air pollution, oxidative damage to DNA, and carcinogenesis. Cancer Lett 2009;266:84–97.
  20. Valko M, Leibfritz D, Moncol J, Mark TDC, Milan M, Joshua T. Free radicals and antioxidants in normal physiological functions and human disease. The International Journal of Biochemistry & Cell Biology 2007;39:44–84.
  21. Dominique Z, Rodrigo F, Alexandros G, Stavroula G, Vasiliki M, Onard S, et al. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chemico-Biological Interactions 2010;188:334–339.
  22. Zieba M, Suwalski M, Kwiatkowska S, Piasecka G, Grzelewska-Rzymowska I, Stolarek R. et al. Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissues and pulmonary parenchyma. Respir Med 2000;94:800-805.
  23. Klaudia J, Marian V. Advances in metal-induced oxidative stress and human disease. Toxicology 2011;283:65–87.
  24. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008;266:37–52.
  25. Galaris D, Skiada V, Barbouti A. Redox signaling and cancer: the role of "labile” iron. Cancer Lett 2008;266:21–29.
  26. Klaunig J, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239–267.
  27. Chen X, Ding YW, Yang G, Bondoc F, Lee, MJ, Yang CS. Oxidative damage in an esophageal denocarcinoma model with rats. Carcinogenesis 2000;21:257-263.
  28. Yarıktas M, Doner F, Dogru H, Aynalı G, Yonden Z, Delibas N. Baş-boyun malign tüm.rlerinde malondialdehit düzeyleri ve antioksidan enzim aktiviteleri. Süleyman Demirel íœniversitesi Tıp Fakültesi Dergisi 2003;10,65-67.
  29. Solmaz F, Aktafl D, Kızılay A, í‡okkeser Y, Oncel S, Ozturan, O, et al. Baş-boyun epidermoid kanserinde dokudaki katalaz ve süperoksit dismutaz aktiviteleri ve malondialdehit düzeyleri. KBB ć°htisas Dergisi 2001;8:397-401.
  30. Durak I, Isik AC, Canbolat O, Akyol O, Kavutcu M. Adenosine deaminase, 5' nucleotidase, xanthine oxidase, superoxide dismutase, and catalase activities in cancerous and noncancerous human laryngeal tissues. Free Radic Biol Med 1993;15:681-4.
  31. Kim SY, Kim HJ, Kang SU, Kim YE, Park JK, Shin YS, et al. Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer. Oncotarget 2015;6:3.
  32. Yen CY, Hou MF, Yang ZW, Tang JY, Li KT, Huang HW, et al. Concentration effects of grape seed extracts in anti-oral cancer cells involving differential apoptosis, oxidative stress, and DNA damage. BMC Complementary and Alternative Medicine 2015;15:94.
  33. Krüger M, Pabst AM, Al"‘Nawas B, Horke S, Moergel M. Paraoxonase"‘2 (PON2) protects oral squamous cell cancer cells against irradiation"‘induced apoptosis. J Cancer Res Clin Oncol 2015;141:1757–1766.
  34. Evan G, Littlewood T. A matter of life and cell death. Science 1998;281:1317-1321.
  35. Laussmann MA, Passante E, Dussmann, H, et al. Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8, Cell Death Differ 2011;18:1584–1597.
  36. Feoktistova M, Geserick P, Kellert B, et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 2011; 43: 449–463.
  37. Tenev T, Bianchi K, Darding M, Broemer M, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs, Mol. Cell 2011;43:432–448.
  38. Hughes MA, Harper N, Butterworth M, et al. Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival, Mol. Cell 2009;35:265–279.
  39. Kuida K, Haydar TF, Kuan CY, Gu Y. et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9, Cell 1998;94:325–337.
  40. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance, Cancer Res 2002;62:924–931.
  41. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma, Nature 2001;409:207–211.
  42. Wolf BB, Schuler M, Li W, et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity, J. Biol. Chem 2001;276:34244–34251.
  43. Park JY, Park JM, Jang JS, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer, Hum. Mol. Genet 2006;15:1963–1971.
  44. Gangwar R, Mandhani A, Mittal RD. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population, Ann. Surg. Oncol 2009;16:2028–2034.
  45. Theodoropoulos GE, Gazouli M, Vaiopoulou A, et al. Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis, Int. J. Colorectal Dis 2011;26:1113–1118.
  46. Liamarkopoulos E, Gazouli M, Aravantinos G, et al. Nikiteas, Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer, Gastric Cancer 2011;14:317–321.
  47. Klebanotf SJ. Myeloperoxidase: Friend and Foe. J Leukoc Biol 2005;77(5): 598-625.
  48. Czygier M, Kamocki Z, Lawicki S, Szmitkowski M. The plasm level of myeloperoxidase (MPO) and total antioxidant status (TAS) ingastric cancer patients after surgery. Przegla d lekarski 2010a;67 (7): 443-445.
  49. Czygier M, Lawicki S, Gacuta-Szumarska E, Bedkowska E, Szmitkowski M. The plasma level of sL-selectin, myeloperoxidase (MPO) and granulocyte-colony stimulating factor (G-CSF) in gynecological cancer patients. Przegla d lekarski 2010b;67(3):184-186.
  50. Czygier M, Lawicki S, Uścinowicz A, Szmitkowski M. The plasma level of sL-selectin, myeloperoxidase and granulocyte-colony stimulating factor (G-CSF) in breast cancer patients in the course of chemotherapy. Przegla d lekarski 2008;65(3):115-118.
Read More

Author Biography

Bedia Cakmakoglu, Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey

Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 789 Download : 327

Most read articles by the same author(s)